The serum concentrations of digoxin-like immunoactivity (DLIA) were measured in 99 patients: 20 healthy volunteers (HV), 15 patients with insulin-dependent diabetes mellitus (IDDM), 14 patients with non-insulin-dependent diabetes mellitus without hypertension taking oral hypoglycemic (OHA) agents (NIDDM/؊ ؊HT), 11 patients with NIDDM without hypertension taking insulin (NIDDM/؊ ؊HT؉ ؉INS), 12 NIDDM patients with hypertension taking OHA (NIDDM/؉ ؉HT), nine NIDDM patients with hypertension taking insulin (NIDDM/؉ ؉HT/؉ ؉INS), 10 patients with essential hypertension with normal insulin levels (HT/؊ ؊HI), and in eight patients with essential hypertension with hyperinsulinemia (HT/؉ ؉HI). The numbers (%) of subjects with DLIA levels above the detection limit of the assay used (> > 0.1 nmol/L) were, in the NIDDM/؊ ؊HT group, 12/14 (85.7%) and in the NIDDM/؉ ؉HT group, 9/12 (75%), significantly higher (P < < .05) than in the HV (7/20; 35%), IDDM (3/15; 20%), and HT/؊ ؊HI groups (2/10; 20%). The number and percentage of subjects with DLIA levels above the detection limit in the HT/؉ ؉HI group was six of eight (75%), significantly (P < < .05) higher than in the IDDM and HT/؊ ؊HI groups, and tended to be higher than in the HV group (P < < .055). Means and SD of serum DLIA levels (nmol/L) in the NIDDM/؊ ؊EH (0.18/0.09) and NIDDM/؉ ؉EH (0.19/0.15) groups were significantly higher (P < < .05) than in the HV (0.09/ 0.07), IDDM (0.05/0.05), and EH/؊ ؊HI (0.06/0.06) groups. DLIA levels in the HT/؉ ؉HI group (0.15/0.12) were significantly higher (P < < .05) than in the IDDM and HT/؊ ؊HI groups. The percentage of DLIA levels above the detection limit, as well as the mean and SD of DLIA in the NIDDM group taking OHA, did not differ from those in subjects taking insulin. In all subjects studied (n ‫؍‬ ‫؍‬ 99), DLIA correlated with Cpeptide (r ‫؍‬ ‫؍‬ 0.30; P < < .01) and glomerular filtration (GF) (r ‫؍‬ ‫؊؍‬ ؊ 0.21; P < < .05). After exclusion of insulintreated patients, DLIA correlated significantly with plasma glucose (PG; r ‫؍‬ ‫؍‬ 0.25; P < < .05), immunoreactive insulin (IRI; r ‫؍‬ ‫؍‬ 0.41; P < < .001), Cpeptide (r ‫؍‬ ‫؍‬ 0.27; P < < .05), and GF (r ‫؍‬ ‫؊؍‬ ؊ 0.26; P < < .05) (n ‫؍‬ ‫؍‬ 64). Correlation of DLIA with IRI (r ‫؍‬ ‫؍‬ 0.33; P < < .05; n ‫؍‬ ‫؍‬ 38) also persisted after exclusion of patients taking insulin and those with DLIA levels below the detection limit. Similarly, DLIA also correlated with C-peptide (r ‫؍‬ ‫؍‬ 0.64; P < < .05) and IRI (r ‫؍‬ ‫؍‬ 0.70; P < < .05) in the subgroup of 10 patients with the highest levels of DLIA (> > 0.25 nmol/L). None of the sera (n ‫؍‬ ‫؍‬ 15) with different DLIA concentrations (0.0 -0.38 nmol/L) exhibited KpNPPase (Na
T he existence of substances crossreacting with antidigoxin and antiouabain antibodies in the plasma of nondigitalized subjects, socalled digoxin-like immunoactivity (DLIA), has been documented in many studies. 1 Moreover, the relation of these substances to several diseases (primarily to essential hypertension) has also been suggested. 2 The chemical nature and biologic properties of DLIA, however, are still a matter of debate. Whereas most authors suggest that DLIA reflects a group of substances that are close to cardiac glycosides (CG), not only immunologically but also structurally and biologically, others emphasize a dissociation between the ability of these substances to react with antidigoxin antibodies and to cause inhibition of Na ϩ -K ϩ -ATPase. [2] [3] [4] [5] [6] The substances with DLIA are known primarily in their relation to essential hypertension. 2, 3 Several recent works, however, have also suggested a relation of DLIA to other diseases, including diabetes mellitus. [7] [8] [9] [10] [11] [12] [13] As is generally known, diabetes and hypertension are very often associated with one another. The mechanisms behind this association (particularly in non-insulin-dependent diabetes mellitus), however, are poorly understood. 25 Although the most important factors appear to be insulin resistance (IR)/compensatory hyperinsulinemia (HI) and reduced renal functions, the possible contribution of substances with DLIA has also been suggested. 7, 8, [12] [13] [14] [15] In this study we measured the serum DLIA concentration in diabetic and hypertensive patients and its relation to insulin, blood pressure (BP), glomerular filtration, and the Na ϩ -K ϩ -ATPase inhibitory activity of serum.
SUBJECTS AND METHODS
The study was carried out in 99 subjects: 20 healthy volunteers (HV), 15 patients with insulin-dependent diabetes mellitus (IDDM), 14 patients with non-insulin-dependent diabetes mellitus (NIDDM) without hypertension treated with diet and oral hypoglycemic (OHA) agents (NIDDM/ϪHT), nine NIDDM patients without hypertension treated with insulin or a combination of OHA plus insulin (NIDDM/ϪHT/ϩINS), 12 NIDDM patients with hypertension treated with OHA (NIDDM/ϩHT), 11 NIDDM patients with hypertension taking insulin or a combination of OHA plus insulin (NIDDM/ϩHT/ϩINS), 10 patients with essential hypertension with normal fasting serum insulin levels (HT/ϪHI), and eight patients with essential hypertension with hyperinsulinemia (HT/ϩHI). All patients were under the care of a diabetologist or general practitioner. None of the subjects had clinical signs of overt diabetic or hypertensive complications, including negative findings of retinopathy and nephropathy (serum creatinine Ͻ 110 mol/L, proteinuria Ͻ 300 mg/24 h). All subjects were in stable health and had no symptoms of congestive heart failure or edema of any etiology. None of the studied subjects was taking digitalis, spironolactone, prednisone, or other steroid preparations. Espoo, Finland) . This assay involves the use of a digoxin antiserum that is unaffected by drugs or by variations in serum protein concentrations. Crossreactivity of the digoxin antiserum with spironolactone, prednisone, progesterone, cortisol, cholesterol, furosemide, and thyroxine is Ͻ 0.0005%. Intra-and interassay coefficient of variation is Ͻ 5% and the average analytical recovery of digoxin is about 101.3 Ϯ 3.14%. The sensitivity of this assay, defined as a smallest detectable concentration equivalent to twice the standard deviation of the zero-binding value, is approximately 0.10 nmol/L. According to our previous study, acute volume expansion induced by physiologic saline infusion led to an increase in the DLIA concentrations measured by this assay. 18 In the same study, DLIA did not correlate with progesterone, estradiol, aldosterone, cortisol, and cholesterol, and in vitro addition of insulin to the sample did not affect DLIA levels. 18 Samples of serum were stored at Ϫ20°C for a period of Ͻ 1 week before the measurement of DLIA.
In 15 subjects, the ability of serum to inhibit Na ϩ -K ϩ -ATPase activity and its relation to DLIA concen-trations was measured. Na ϩ -K ϩ -ATPase activity was estimated on the basis of measurement of p-nitrophenylphosphate (pNPP) hydrolysis, as K-pNPPase activity, 20, 21 in synaptosomes 1 and synaptosomes 2 prepared from the rat brain tissue homogenates according to Edelman et al's procedure. 19 In brief, Na ϩ -K ϩ -ATPase is known to hydrolyze not only ATP but also nonnucleotide substrates such as p-nitrophenyl phosphate (pNPP). In the presence of this substrate, very small concentrations on Na ϩ are able to provide the optimal rate of hydrolysis. This reaction, which is called K-phosphatase, is performed by the enzyme in E2 conformation. K-phosphatase activity is measured continuously by following the increase in absorbance at 410 nm due to the release of the p-nitrophenolate anion from p-nitrophenyl phosphate. 20, 21 The incubation medium for the K-pNPPase activity measurement contained 100 mmol/L KCl, 20 nmol/L MgCl 2 , 7.5 mmol/L pNPP, and 30 mmol/L imidazole (pH ϭ 7.4). To determine total and ouabaininsensitive Mg 2ϩ -dependent K-pNPPase activity, two probes were prepared for each brain sample. In both cases 150 g of synaptosomal protein was added to the 2 mL of incubation medium. To determine the activity of ouabain-insensitive Mg 2ϩ -dependent K-pNPPase, ouabain (the specific inhibitor of Na ϩ -K ϩ -ATPase) was added to the reaction medium at a final concentration 0.5 mmol/L. Both probes were preincubated at room temperature for 7 min and after that at 37°C in a spectophotometer for 3 min. The reaction was started by the addition of pNPP to each probe. The rate of p-nitrophenyl accumulation was registered during 15 min. All measurements were carried out at 37°C using an LKB Spectrophotometer (Ultrospec III, Pharmacia LKB, Cambridge, England) and the Enzyme Kinetics program (Biokin Ltd., Madison, WI) for Microsoft (Redmond, WA) Windows. The activities of ouabain-insensitive and total K-pNPPase are known to be in direct proportion to the rate of pNPP hydrolysis with or without ouabain, respectively. These activities were calculated as the accumulation of p-nitrophenol in mmol/mg protein/h. The activity of ouabain-sensitive K-pNPPase was calculated as the difference between total and ouabain-insensitive Mg 2ϩ -dependent K-pNPPase. 20, 21 The ability of serum to inhibit KpNPPase activity was determined using the abovedescribed system, after the addition of 100 L serum into the reaction medium.
Plasma glucose was measured in capillary blood using a glucose oxidase method with electrochemical detection; IRI level was measured in venous serum using insulin RIA (Diagnostic Products Corporation, Los Angeles, CA). C-peptide level was measured in venous serum using C-peptide RIA (Immunotech, Czech). Serum Chol, TG, and Cr were measured in venous blood by the Monarch 2000 automatic analyzer (Instrumentation Laboratory, Lexington, MA). GF was estimated on the basis of the formula of Gault et al. 22 All biochemical parameters were measured in a blood sample drawn in the fasting state. Diabetes mellitus was classified according to the criteria of the World Health Organization (WHO). 16 Hypertension was defined as a systolic blood pressure (SBP) Ն 140 mm Hg or a diastolic blood pressure (DBP) Ն 90 mm Hg.
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The BP on the day of the study was measured in a seated position after 10 min of rest, using a mercury sphygmomanometer (15 min before drawing the blood sample), and an average of three measurements was used. The goals of the study were to compare DLIA concentration among the healthy diabetic and hypertensive subjects, and to assess the relation of DLIA to PG, CP, IRI, Cr s , GF, SBP, DBP, and to the Na ϩ -K ϩ -ATPase inhibitory activity of serum. Informed consent was obtained from each subject and the study was approved by the Institutional Ethics Committee.
Statistical Analysis
Values are expressed as mean Ϯ SD. Statistical comparison of results among the study groups was done by ANOVA (with least subsequent significant difference), pair t test, and 2 -test, as appropriate. Correlations were assessed using regression analysis. The level of significance was set at p Ͻ .05; the software used was CSS.PC (Statsoft Inc., Tulsa, OK). Tables 1-6 . The numbers of subjects (percentages) with serum DLIA concentrations above the detection limit (Ͼ 0.1 nmol/L) were in the NIDDM/ϪHT group, 12/14 (85.7%), and in the NIDDM/ϩHT group, 9/12 (75%), significantly higher (P Ͻ .05) than in the HV (7/20 [35%]), IDDM (3/15 [20%]), and HT/ϪHI (2/10 [20%]) groups. The number of subjects (percentage) of DLIA above the detection limit in the HT/ϩHI group, 6/8 (75%), was significantly higher (P Ͻ .05) than in the IDDM and HT/ϪHI groups, and tended to be higher than in the HV group (P Ͻ .055) (Table 1; Figure 1 ). Means/SD of the serum DLIA concentration (nmol/L) in the NIDDM/ϪEH (0.18/0.09) and NIDDM/ϩEH (0.19/ 0.15) groups were significantly higher (P Ͻ .05) than in the HV (0.09/0.07), IDDM (0.05/0.05), and EH/ϪHI (0.06/0.06) groups. DLIA levels in the HT/ϩHI group (0.15/0.12) were significantly higher (P Ͻ .05) than in the IDDM and HT/ϪHI patients (Table 1, Figure 2 ). The percentage of DLIA above the detection limit, as well as the mean/SD of DLIA in NIDDM treated with OHA, did not differ from those treated with insulin (Table 1) . Clinical characteristics of patients with the highest levels of DLIA (Ͼ 0.25 nmol/L) are depicted in Table 2 . Eight of 10 (80%) of these patients belonged to the NIDDM cohort and 8/10 (80%) were HT; 6/10 (60%) were NIDDM/ϩHT. Eight of 10 (80%) of these patients had HI and 6/10 (60%) had GF Ͻ 1.4 mL/sec. Also, in comparison to HV these patients had significantly (P Ͻ .05) higher age, PG, IRI, CP, TG, Chol, Cr s , SBP, and DBP, and lower GF (Table 3) . A comparison of NIDDM patients with low DLIA (Ͻ 0.1 nmol/L) to those with high levels of DLIA (Ͼ 0.2 nmol/L) showed that these subgroups differed in GF (P Ͻ 0.05). Differences in other measured parameters were not significant. In all studied subjects (n ϭ 99) DLIA correlated significantly only with C-peptide (r ϭ 0.30; P Ͻ .01) and GF (r ϭ Ϫ0.21; P Ͻ .05) ( Table 4 ). After exclusion of insulin-treated patients, DLIA significantly correlated with PG (r ϭ 0.25; P Ͻ .05), IRI (r ϭ 0.41; P Ͻ .001), C-peptide (r ϭ 0.27; P Ͻ .05), and GF (r ϭ Ϫ0.26; P Ͻ .05) (n ϭ 64). Correlations of DLIA with IRI (r ϭ 0.33; P Ͻ .05; n ϭ 38) persisted also after exclusion of insulin-treated patients and those with DLIA levels below the limits of detection. Similarly, the correlation of DLIA with IRI (r ϭ 0.70; P Ͻ .05) and C-peptide (r ϭ 0.64; P Ͻ .05) was also seen in 10 patients with the highest DLIA concentrations (Ͼ 0.25 nmol/L) ( Table  4) .
RESULTS

Results are given in
None of the sera (n ϭ 15) exhibited statistically significant K-pNPPase inhibitory activity and DLIA concentrations in serum did not correlate with K-pNPPase inhibitory activity ( Table 5) . Results of the other measured parameters (age, BMI, PG, IRI, CP, TG, Chol, Cr, GF, SBP, and DBP) are depicted in Table 1 . Correlations of IRI, SBP, and DBP are given in Table 6 .
DISCUSSION
The elevation of DLIA is in general attributed to sodium retention and volume expansion. 1 This association has been documented in many studies including our previous work, in which acute isotonic saline infusion led to a significant increase in DLIA concentrations, as measured by the same assay as that used in this study. 18 In diabetic subjects, the sodium retention and volume expansion are ascribed to hyperinsulinemia (compensatory in NIDDM or due to insulin treatment in IDDM) 23 or to reduced renal functions (as a consequence of diabetic nephropathy). The findings of an elevated DLIA in NIDDM and HT/ϩHI patients, and the correlation of DLIA with insulin (C-peptide) and glomerular filtration in our study, are in agreement with this scenario as well as with the findings of other authors who have assessed DLIA in diabetics. 6 -15 On the other hand, we did not find elevated DLIA levels in IDDM subjects, as documented by some of these authors. 6, 8 Similarly, we did not find differences in DLIA between NIDDM taking oral hypoglycemic agents and NIDDM taking insulin. Moreover, the correlation of DLIA with IRI was seen only after the exclusion of insulin-treated patients. This suggests that elevation of DLIA could be related to endogenous hyperinsulinemia but probably not to hyperinsulinemia induced by insulin therapy.
The issue of whether the increase of DLIA in our patients is just a secondary reflection associated with HI and reduced GF, or whether it also has pathophysiologic consequences, remains unclear. Several explanations suggesting a negative 7, 8, 14 [2] [3] [4] [5] This is also why the substances with DLIA were considered to be hypertension-promoting factors and have been introduced into pathogenetic schemes of hypertension. [2] [3] [4] [5] Despite the fact that NIDDM is very often associ- ated with hypertension, the mechanisms behind this association are not clear and include the contributions of many factors. Of them, the insulin resistance/compensatory HI with associated abnormalities (increased sodium retention, increased sympathetic activity, etc.) and reduced renal function are considered among the most important. However, due to the fact that insulin usually acts as a vasodilator (probably via stimulation of Na ϩ -K ϩ -ATPase activity at the endothelial level), its role in this association seems to be controversial. [23] [24] [25] Thus, it is intriguing to assume that the relation of HI to BP could be mediated by other factor(s) or mechanisms that are elicited by HI and counteract the insulin vasodilatory effects. In experiments, the plant-derived ouabain (a member of the cardiac glycosides [CG] family) has been found to abolish insulin-induced vasodilation. 24 In this aspect, the similar effects of substances with DLIA (assuming that they are close to CG) has also been suggested. 7, 8, 14, 15 In our study, the analysis of 10 subjects with the highest DLIA (Ͼ 0.25 nmol/L) showed that all of them had either NIDDM or HT/ϩHI, and most of them had both. This could argue indirectly for the possible role of DLIA as one of the factors connecting NIDDM with HT. On the other hand, no differences in DLIA concentrations were found between NIDDM/ϩHT and NIDDM/ϪHT, and DLIA did not correlate with BP. There are at least two possible explanations for the lack of correlation between DLIA and BP in our study. First, the values of blood pressure in patients with HT were affected by antihypertensive treatment and the washout period of 24 h was too short to reduce this effect. Second, the DLIA levels measured in our study did not reflect hypertension-promoting substances. Nevertheless, DLIA correlated significantly with HI and reduced GF, which are common findings for both NIDDM and HT/ϩHI patients and are strongly correlated also with both SBP and DBP.
As another potential common underlying mechanism connecting NIDDM with HT, the reduced Na , which are typical for both NIDDM and HT/ϩHI subjects, are also under investigation. 14,15,26 -29 In this aspect, DLIA as a putative inhibitor of Na ϩ -K ϩ -ATPase could represent one of the factors leading to such defects. However, there are also several studies that emphasize a dissociation between DLIA and Na ϩ -K ϩ -ATPase inhibitory activity. 5, 6, 15, 30 Similarly, in this study we failed to demonstrate K-pNPPase inhibitory activity in the serum of NIDDM patients and its correlation with DLIA concentrations. Though this could suggest that the DLIA levels measured in our study did not reflect inhibitors of Na ϩ -K ϩ -ATPase, there are also several other possible explanations. First, that subnanomolar concentrations of DLIA were too low to inhibit Na ϩ -K ϩ -ATPase, or, second, that the method used for the measurement of Na ϩ -K ϩ -ATPase activity in our study was not sensitive enough for our purposes. Thus, it seems that the discrepancies among the studies could depend on the methods used for assessment of digitalis-like immunologic (DLIA) and digitalis-like biologic (inhibition of Na ϩ -K ϩ -ATPase) activity. We incline to the view that DLIA and Na ϩ -K ϩ -ATPase inhibitory activity should not be interpreted as equivalent. Similarly, the explanation of findings in our study should be careful and remains only speculative. Nevertheless, the elevated concentration of substances with DLIA and their interference with antidigoxin antibodies may, at the least, falsely elevate total digoxin concentrations and affect therapeutic monitoring of digitalization. 9 This fact may have a direct application in clinical practice.
In conclusion, this work demonstrates elevated serum DLIA levels in NIDDM and hypertensive patients with hyperinsulinemia, and a correlation with insulin levels and GF. However, due to the fact that the chemical nature and biologic properties of DLIA are still a matter of debate, it is too early to speculate whether the elevation of DLIA in these subjects is just a secondary reflection associated with HI and reduced renal functions, or whether it also has pathophysiologic consequences. Nevertheless, in both cases the elevated concentration of substances with DLIA and their interference with antidigoxin antibodies may affect therapeutic monitoring of digitalization in NIDDM and hypertensive patients. In addition, the elevated DLIA could subclassify these patients. The significance of such subclassification (pathophysiologic, therapeutic, or prognostic), however, will require further investigation. 
